AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04377269 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Taping and Bandaging
Description: Ankle taping: a hard preventive Zinc oxide tape was used. The taping procedures consisted of three separate steps. 1) included the application of the anchor tape. 2) application of the stirrup tape. The stirrup tape was performed two times by holding the foot in a neutral position and the tape is placed as it passed through the medial side of the ankle (under the foot), just over the heel area (posterior one-third of the foot) and up along the lateral side of the ankle. Bandaging: standard 10cm width elastic bandage used. The bandage wrapped around the ankle joint in the form of an 8-figure. Bandage started from the forefoot, moving diagonally upwards and steeply enough to go well above the heel to end around the lower calf area to form an anchor. Then, it moved diagonally down across the mid-foot. Placebo: 10cm long tape was applied on the lateral side of the leg, just above the lateral malleolus and aligned with peroneus longus tendon
Study NCT03024255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI-4000 gel, 5%
Description: BBI-4000 gel, 5% applied once to each axilla daily
Study NCT03024255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI-4000 gel, 10%
Description: BBI-4000 gel, 10% applied once to each axilla daily
Study NCT03024255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI-4000 gel, 15%
Description: BBI-4000 gel, 15% applied once to each axilla daily
Study NCT03024255 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle (Placebo)
Description: Placebo, applied once to each axilla daily
Study NCT03967756 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automatic polyp detection system
Description: When colonoscopists withdraw the colonoscopies and inspect the colons, the video streaming of colonoscopies was real-time switched to the automatic polyp detection system, which made it feasible to detect lesions in real time. When any potential polyp is detected by the system， there will be a tracing box on an adjacent monitor to locate the lesion with a simultaneous sound alarm.
Study NCT00599170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 IV
Study NCT03713216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naldebain
Description: 150 mg Nalbuphine sebacate
Study NCT03713216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Morphine
Study NCT02685995 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VectorFlow TDC
Description: TDC insertion with VectorFlow will be in accordance with its FDA-approved indication under moderate sedation or general anesthesia with local anesthesia using 1% lidocaine in per institutional protocol. Following TDC insertion, the catheter may be used immediately. The goal of HD is typically to achieve a target effective blood flow of 300mL/min within the first 3 hemodialysis sessions. The dialysis records from each of the first three HD sessions will be reviewed by the study coordinator for (A) Blood flow rate (QB), (B) Arterial and venous lumen pressures, (C) Kt/V, and (D) Urea reduction ratio (URR). Additionally, need and use of thrombolytic infusion (ie t-PA) (other than single dose injection) to restore or improve patency and/or need for catheter exchange.
Study NCT02685995 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Palindrome TDC
Description: TDC insertion with Palindrome will be in accordance with its FDA-approved indication under moderate sedation or general anesthesia with local anesthesia using 1% lidocaine in per institutional protocol. Following TDC insertion, the catheter may be used immediately. The goal of HD is typically to achieve a target effective blood flow of 300mL/min within the first 3 hemodialysis sessions. The dialysis records from each of the first three HD sessions will be reviewed by the study coordinator for (A) Blood flow rate (QB), (B) Arterial and venous lumen pressures, (C) Kt/V, and (D) Urea reduction ratio (URR). Additionally, need and use of thrombolytic infusion (ie t-PA) (other than single dose injection) to restore or improve patency and/or need for catheter exchange.
Study NCT03625141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: 60 mg (three tablets of 20 mg each) orally (PO) once a day (QD) on Days 1-21 of each 28-day cycle.
Study NCT03625141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be given at a fixed dose of 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.~Only for cohort 2, no dose of atezolizumab will be given during the run-in period (cycle 1).
Study NCT03625141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Participants will receive vemurafenib 960 mg (four 240 mg tablets) orally (PO) twice daily (BID) on days 1-21 of the run-in period (cycle 1); thereafter, they will receive vemurafenib 720 mg dose (three 240 mg tablets) PO BID on days 22-28 of cycle 1 and on days 1-28 of all subsequent cycles.
Study NCT04237818 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink
Description: consume 2 bottle (30 mL) per day for 56 days
Study NCT04237818 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chenopodium Formosanum and Fagopyrum Esculentum Extract drink
Description: consume 2 bottle (30 mL) per day for 56 days
Study NCT00703469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDX1106-02
Description: Single dose
Study NCT00703469 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo single dose
Study NCT03169049 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-Frequency Stimulation
Description: high-Frequency electrical stimulation over superficial ulnar and median nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
Study NCT03169049 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham Stimulation
Description: Sham transcutaneous electrical stimulation over superficial ulnar and median nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
Study NCT01736631 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT)
Description: The CBT intervention will follow the model of social phobia by Clark \& Wells (Clark \& Wells, 1995; Clark, 2005). The main elements of CBT for social phobia include reducing self-focus, dropping safety behaviours, and testing negative cognitions.
Study NCT02928926 — intervention group
Intervention type: OTHER
Intervention: intravenous thrombolysis
Description: patients who are eligible with intravenous thrombolysis or admitted within the timeframe to receive thrombolysis but not eligible due to other reasons
Study NCT03513250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyoscine-n-butylbromide
Description: one ampoule of 20 mg of hyoscine-n-butylbromide (Buscopan, 20mg/Ampoule, CID/Boehringer ) will be administered intravenously immediately before the end of the cesarean section.
Study NCT03513250 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: an equal volume(1 ml ) of normal saline will be administered before the end of cesarean section.
Study NCT01312324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neoadjuvant docetaxel/cisplatin
Description: 3 cycles of docetaxel plus cisplatin docetaxel 75mg/m2 D1 cisplatin 75mg/m2 D1 every 3 weeks
Study NCT01667029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Study NCT01667029 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02780310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Study NCT01854593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 0.16 mg/0.05 ml bevacizumab (single injection on 1 day before operation)
Study NCT01854593 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vitrectomy
Description: vitrectomy of 25 gauge system.
Study NCT01854593 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Vitrectomy
Description: vitrectomy of 25 gauge system.
Study NCT01854593 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Description: Sham injection one day before vitrectomy
Study NCT01147406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N6022
Description: This is an injectible formulation which will be given at 5, 15 \& 45 mg over 1, 3 and 9 minutes respectively, in single ascending doses.
Study NCT01147406 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This will be 0.9% normal saline given over 1, 3, or 9 minutes IV bolus.
Study NCT04564716 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gam-COVID-Vac
Description: vaccine for intramuscular injection
Study NCT04564716 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo comparator
Study NCT03400072 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised APA program
Description: Exercise training program will consist of one supervised demonstration session with the APA professional, thereafter the training will be continued as unsupervised, home-based exercise training sessions; in addition, patients will attend weekly supervised, hospital-based exercise sessions in groups of patients.
Study NCT03307538 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy
Description: 15 fractions of 3-4,5 Gy (risk-adapted)
Study NCT02897115 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Administered every other week by subcutaneous injection for up to 48 weeks, depending on participants' disease activity.
Study NCT02897115 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-steroidal Anti-inflammatory Drugs (NSAIDs)
Description: ASAS recommended NSAID doses to treat axial spondyloarthritis.
Study NCT02982629 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reminder letter Intervention
Description: Patients in this group receive letters and phone calls to reschedule missed follow-up appointments.
Study NCT02982629 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Reminder letter Intervention
Description: Patients in this group receive letters and phone calls to reschedule missed follow-up appointments.
Study NCT03420742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam syrup.
Study NCT03420742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib
Description: Brigatinib tablets.
Study NCT02000401 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ketorolac Tromethamine
Study NCT02831218 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: QCA and Aspirin
Description: QCA(quantitative coronary angiography) guided BVS implantation and all patients are treated with dual antiplatelet therapy (aspirin 100mg/day and clopidogrel 75mg per day\[or ticagrelor 90mg po bid\]) for 12 months after BVS implantation, and randomized to either aspirin alone (aspirin 100mg/day) or clopidogrel alone (clopidogrel 75mg /day) for the next 4 years.
Study NCT02831218 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: QCA and Clopidogrel
Description: QCA(quantitative coronary angiography) guided BVS implantation and all patients are treated with dual antiplatelet therapy (aspirin 100mg/day and clopidogrel 75mg per day\[or ticagrelor 90mg po bid\]) for 12 months after BVS implantation, and randomized to either aspirin alone (aspirin 100mg/day) or clopidogrel alone (clopidogrel 75mg /day) for the next 4 years.
Study NCT02831218 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Imaging guided and Aspirin
Description: BVS size and length were selected by on-line IVUS(intravascular ultrasound) or OCT(optical coherence tomography) measurements and all patients are treated with dual antiplatelet therapy (aspirin 100mg/day and clopidogrel 75mg per day\[or ticagrelor 90mg po bid\]) for 12 months after BVS implantation, and randomized to either aspirin alone (aspirin 100mg/day) or clopidogrel alone (clopidogrel 75mg /day) for the next 4 years.
Study NCT02831218 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Imaging guided and Clopidogrel
Description: BVS size and length were selected by on-line IVUS(intravascular ultrasound) or OCT(optical coherence tomography) measurements and all patients are treated with dual antiplatelet therapy (aspirin 100mg/day and clopidogrel 75mg per day\[or ticagrelor 90mg po bid\]) for 12 months after BVS implantation, and randomized to either aspirin alone (aspirin 100mg/day) or clopidogrel alone (clopidogrel 75mg /day) for the next 4 years.
Study NCT02745886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin 0.85 twice daily for 6 months
Study NCT02745886 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Calorie restriction
Study NCT03508414 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ketogenic diet
Description: Patients receive a ketogenic diet, which is carbohydrate-reduced with a high amount of fat.
Study NCT03508414 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent therapeutical fasting
Description: Patients fast for 1 week every six months. Additionally, the patients do an intermittent fasting, that is to say they do not eat for at least 14 hours a day.
Study NCT03508414 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator
Description: The control group is receiving a vegetarian-focused diet according to the current recommendations of the German Society for Nutrition (DGE) for MS patients.
Study NCT02229539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxepin hydrochloride oral solution
Description: 2.5 mL (25 mg) doxepin and 2.5 mL water administered orally
Study NCT02229539 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DLA (diphenhydramine, lidocaine and antacids) rinse
Description: 5.0 mL administered orally
Study NCT02229539 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2.5 mL placebo and 2.5 mL water administered orally
Study NCT02804230 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuro Ablation - Functional
Description: MR-Guided Focused Ultrasound
Study NCT04198636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY01011
Description: LY01011 injection (120mg) by subcutaneous injection once on the first day subcutaneous injection of 120 mg (1.7 ml)only once
Study NCT04198636 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xgeva 120 MG in 1.7 ML Injection
Description: Xgeva® injection (120mg) by subcutaneous injection once on the first day subcutaneous injection of 120 mg (1.7 ml)only once
Study NCT01194336 — intervention group
Intervention type: DRUG
Intervention: Huperzine A
Description: dosage form: tablet dose frequency: once only
Study NCT01194336 — intervention group
Intervention type: DRUG
Intervention: Donepezil
Description: dosage form: tablet dosage frequency: once only
Study NCT01194336 — intervention group
Intervention type: DRUG
Intervention: Galantamine
Description: dosage form: tablet dosage frequency: once only
Study NCT01194336 — intervention group
Intervention type: OTHER
Intervention: Placebo
Description: dosage form: tablet dosage frequency: once only
Study NCT03989622 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: evaluation of the visual field on the ground
Description: evaluation of the visual field on the ground
Study NCT01765582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: Participants in Arm A will receive 3200 milligrams per square meter (mg/m\^2) by 48-hour continuous intravenous (IV) infusion every 2 weeks, during the 4-6 months' induction followed by maintenance therapy including bolus dose of 400 mg/m\^2, followed by a 46-hour continuous infusion (2400 mg/m\^2) every 2 weeks per investigator's discretion. Participants in Arm B and C will receive a bolus dose of 400 mg/m\^2, followed by a 46-hour continuous infusion (2400 mg/m\^2) every 2 weeks during the 4-6 months of induction and maintenance per investigator's discretion.
Study NCT01765582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Participants will receive 5 mg/kg IV every 2 weeks during the first 4-6 months induction phase, followed by 5 mg/kg IV every 2 weeks or 7.5 mg/kg IV every 3 weeks during maintenance therapy, and 2.5 mg/kg per week reinduction after disease progression.
Study NCT01765582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Participants will receive 1000 or 850 mg/kg orally twice daily as per investigator's discretion on Day 1 to 14, repeated every 3 weeks in maintenance phase.
Study NCT01765582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: Participants will receive IV infusion of 165 mg/m\^2 over 1 hour every 2 weeks (Arm A) or IV infusion of 180 mg/m\^2 over 1 hour in 2 x 2 weeks cycles alternating months (in Arm B), during 4-6 months induction phase.
Study NCT03631264 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesiotape
Description: Kinesiotape application to masseter and hyoid muscles of late preterm infants to improve sucking and swallowing.
Study NCT01765582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: folinic acid
Description: Participants will receive IV infusion of 200 mg/m\^² (Arm A) or 400 mg/m\^2 (Arm B or C) over 2 hours every 2 weeks, during 4-6 months induction phase followed by IV infusion of 400 mg/m\^2 in the maintenance therapy.
Study NCT01765582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Participants will receive 85 mg/m\^2 over 2 hours as IV infusion every 2 weeks (Arm A, C ) or 2 x 2 week cycles alternating months (Arm B), during 4-6 months induction phase .
Study NCT00999232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythromycin
Description: Subjects receive 4x250mg erythromycin i.v. daily after intubation of a self-propelled feeding tube
Study NCT00999232 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects receive 4x placebo i.v. daily after intubation of a self-propelled feeding tube
Study NCT03220178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib 125mg/day orally dosed for 3 weeks followed by 1 week off; repeated for each treatment cycle
Study NCT03220178 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Palbociclib
Description: Palbociclib 125mg/day orally dosed for 3 weeks followed by 1 week off; repeated for each treatment cycle
Study NCT03220178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500mg per use-after first application, again at wk2, then once per month
Study NCT03220178 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fulvestrant
Description: 500mg per use-after first application, again at wk2, then once per month
Study NCT03220178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: 1mg per day
Study NCT03220178 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Anastrozole
Description: 1mg per day
Study NCT03220178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2,5mg/day
Study NCT03220178 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Letrozole
Description: 2,5mg/day
Study NCT03220178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: 25mg/day
Study NCT03220178 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Exemestane
Description: 25mg/day
Study NCT03674684 — intervention group
Intervention type: OTHER
Intervention: hydroxyethyl starch
Description: After induction to anaesthesia patients received either hydroxyethyl starch or gelatin or crystalloids
Study NCT01416272 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KeraSoft IC Soft Contact Lenses
Description: Lenses will be worn between 8 and 16 hrs each day, for 12 months
Study NCT01964430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: nab-Paclitaxel 125 mg/m\^2 on Days 1, 8, and 15 of every 28 day treatment cycle by intravenous (IV) administration for a total of 6 cycles.
Study NCT01964430 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2 on Days 1, 8, and 15 of a 28 day cycle by IV administration for a total of 6 cycles.
Study NCT01964430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2 on Days 1, 8, and 15 of a 28 day cycle by IV administration for a total of 6 cycles.
Study NCT02571075 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture
Description: The ear will be cleaned with alcohol prior to insertion of the needles. Five sterile, single-use, gold needles will be placed in each ear according to the figure below. The needles penetrate about a millimeter (or 4/100ths of an inch) into the skin.
Study NCT01306903 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MECC
Description: Minimized extracorporeal circulation
Study NCT01306903 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: MOPS
Description: Modified and optimized perfusion system Frankfurt